Phosphorylated VEGFR2 and hypertension: Potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy

Breast Cancer Research and Treatment

Volumn 143, Issue 1, 2014, Pages 141-151

  Fan, Minhao ^a   Zhang, Jian ^a   Wang, Zhonghua ^a   Wang, Biyun ^a   Zhang, Qunlin ^a   Zheng, Chunlei ^a   Li, Ting ^a   Ni, Chen ^a   Wu, Zhenhua ^a   Shao, Zhimin ^a,b   Hu, Xichun ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Advanced breast cancer (ABC); Apatinib; Biomarker; Tyrosine kinase inhibitor (TKI); VEGF dependency

Indexed keywords

APATINIB; BIOLOGICAL MARKER; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACKACHE; BLEEDING; BREAST CANCER; CANCER SURVIVAL; CONFUSION; CONSTIPATION; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAND FOOT SYNDROME; HEADACHE; HEART DISEASE; HOARSENESS; HUMAN; HYPERTENSION; HYPOKALEMIA; LEG PAIN; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEINURIA; RASH; THROMBOCYTOPENIA; ULCER; VOMITING;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CYTOKINES; FEMALE; HUMANS; HYPERTENSION; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PHOSPHORYLATION; PYRIDINES; RISK FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84892808045     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2793-6     Document Type: Article

References (53)

1. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA (2005) Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol 34:405-412
2. Gasparini G (2000) Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5(Suppl 1):37-44
3. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6
4. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4-25
5. Rosen LS (2005) VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 10:382-391
6. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676
7. Miles DW, Chan A, Dirix LY et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239-3247
8. Robert NJ, Dieras V, Glaspy J et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252-1260
9. Bergh J, Bondarenko IM, Lichinitser MR et al (2012) First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 30:921-929
10. Yardley DA, Dees EC, Myers SD et al (2012) Phase II open-label study of sunitinib in patients with advanced breast cancer. Breast Cancer Res Treat 136:759-767
11. Burstein HJ, Elias AD, Rugo HS et al (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810-1816
12. Bianchi G, Loibl S, Zamagni C et al (2009) Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 20:616-624
13. Moreno-Aspitia A, Morton RF, Hillman DW et al (2009) Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 27:11-15
14. Barrios CH, Liu MC, Lee SC et al (2010) Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121:121-131
15. Motzer R, Nosov D, Eisen T (2013) Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. J Clin Oncol. doi: 10.1200/JCO.2012.47.4940
16. Motzer R, Eisen T, Hutson T (2013) Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma. J Clin Oncol 31(suppl 6):350
17. Hutson T, Gallardo J, Lesovoy V (2013) Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 31(suppl 6):LBA348
18. Poprach A, Pavlik T, Melichar B et al (2012) Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann Oncol 23:3137-3143
19. Schneider BP, Wang M, Radovich M et al (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672-4678
20. Osterlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T, Bono P (2011) Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 104:599-604
21. Gianni L, Romieu GH, Lichinitser M et al (2013) AVEREL: a randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 31:1719-1725
22. Van Cutsem E, de Haas S, Kang YK et al (2012) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 30:2119-2127
23. Cohen EE, Davis DW, Karrison TG et al (2009) Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 10:247-257
24. Wedam SB, Low JA, Yang SX et al (2006) Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24:769-777
25. Murukesh N, Dive C, Jayson GC (2010) Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 102:8-18
26. Deprimo SE, Bello CL, Smeraglia J et al (2007) Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 5:32
27. Kelly RJ, Rajan A, Force J et al (2011) Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. Clin Cancer Res 17:1190-1199
28. Zhu AX, Sahani DV, Duda DG et al (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27:3027-3035
29. Hanrahan EO, Ryan AJ, Mann H et al (2009) Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 15:3600-3609
30. Jonasch E, Corn P, Pagliaro LC et al (2010) Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 116:57-65
31. Benelli R, Lorusso G, Albini A, Noonan DM (2006) Cytokines and chemokines as regulators of angiogenesis in health and disease. Curr Pharm Des 12:3101-3115
32. Dimberg A (2010) Chemokines in angiogenesis. Curr Top Microbiol Immunol 341:59-80
33. Neufeld G, Kessler O (2006) Pro-angiogenic cytokines and their role in tumor angiogenesis. Cancer Metastasis Rev 25:373-385
34. Tian S, Quan H, Xie C et al (2011) YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci 102:1374-1380
35. Zhang L, Shi M, Huang C et al (2012) A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens. J Clin Oncol 30:7548
36. Li J, Qin S, Xu J et al (2013) Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm phase II trial. J Clin Oncol 31:3219-3225
37. Machado DE, Berardo PT, Palmero CY, Nasciutti LE (2010) Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases. J Exp Clin Cancer Res 29:4
38. Wang CJ, Zhou ZG, Holmqvist A et al (2009) Survivin expression quantified by Image Pro-Plus compared with visual assessment. Appl Immunohistochem Mol Morphol 17:530-535
39. Li J, Zhao X, Chen L et al (2010) Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. Bmc Cancer 10:529
40. Li J, Qin S, Xu J et al (2011) A randomized, double-blind, multicenter, phase II, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma. J Clin Oncol 29:4019)
41. Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G (2007) Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 50:203-218
42. Pistol-Tanase C, Raducan E, Dima SO et al (2008) Assessment of soluble angiogenic markers in pancreatic cancer. Biomark Med 2:447-455
43. Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845
44. Cameron D, Brown J, Dent R et al (2013) Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. doi: 10.1016/S1470-2045(13)70335-8
45. Hulse RE, Kunkler PE, Fedynyshyn JP, Kraig RP (2004) Optimization of multiplexed bead-based cytokine immunoassays for rat serum and brain tissue. J Neurosci Methods 136:87-98
46. Pircher A, Hilbe W, Heidegger I, Drevs J, Tichelli A, Medinger M (2011) Biomarkers in tumor angiogenesis and anti-angiogenic therapy. Int J Mol Sci 12:7077-7099
47. Giatromanolaki A, Koukourakis MI, Sivridis E et al (2012) Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials. Br J Cancer 107:1044-1050
48. Weigand M, Hantel P, Kreienberg R, Waltenberger J (2005) Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 8:197-204
49. Kranz A, Mattfeldt T, Waltenberger J (1999) Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int J Cancer 84:293-298
50. Liang Y, Brekken RA, Hyder SM (2006) Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. Endocr Relat Cancer 13:905-919
51. George S, Reichardt P, Lechner T, Li S, Cohen DP, Demetri GD (2012) Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol 23:3180-3187
52. Tang JR, Markham NE, Lin YJ et al (2004) Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol 287:L344-L351
53. Maitland ML, Kasza KE, Karrison T et al (2009) Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 15:6250-6257